Skip to main content

Table 1 Baseline population characteristics according to arm of treatment

From: Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial

Characteristics

Total (n = 229)

CLARITHRO

n = 6127%

CIPRO

n = 5624%

METRO

n = 5725%

CIPRO-Plus

n = 5524%

Demographic characteristics

Male (%)

35

43

43

35

35

Age, years mean ± SD

42 ± 16

40 ± 15

44 ± 16

41 ± 16

41 ± 17

Married (%)

57

52

68

60

49

CommunityHealth Insurance (%)

88

85

88

93

87

Access to endoscopy (days)

2.2 ± 3.1

1.9 ± 0.6

2.8 ± 6

2.3 ± 1.7

1.9 ± 0.6

Medical history

PPI or H2 blocker before (%)

77

74

79

79

78

Triple therapy before (%)

17

13

23

16

18

Antibiotics before (%)

14

13

13

13

18

Symptoms

Epigastric pain (%)

96

97

95

95

96

Vomiting (%)

30

27

38

19

35

Hematemesis (%)

8

10

9

4

9

Melena (%)

2

2

4

2

2

Endoscopy finding

Normal endoscopy (%)

16

18

14

21

11

Gastritis (%)

56

41

55

61

67

Gastric ulcer (%)

11

10

14

14

7

Duodenal ulcer (%)

30

41

36

25

16

Initially positive FAT (%)

37

39

39

39

31

Baseline HRQoLtotal group(mean ± SD score)

76 ± 11

77 ± 13

76 ± 12

76 ± 8

78 ± 12

Baseline HRQoLin functional dyspepsia (n = 37) (mean ± SD score)

73 ± 12

71 ± 9

70 ± 17

74 ± 10

76 ± 14

  1. Baseline characteristics of the intention to treat population were not significantly different, except for gastritis (CIPRO Plus and METRO were significantly different from CLARITHRO, with p = 0.005 and p = 0.02, respectively) and for duodenal ulcer (CIPRO Plus was significantly different from CLARITHRO, p = 0.004).Abbreviations: SD Standard deviation, FAT Fecal Antigen Test, PP Proton Pump Inhibitors